These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22608247)

  • 21. Ferucarbotran-enhanced magnetic resonance imaging versus gadoxetic acid-enhanced magnetic resonance imaging for the preoperative detection of hepatocellular carcinoma: initial experience.
    Lee JY; Kim SH; Jeon YH; Lee J; Kim MJ; Choi D; Lee WJ
    J Comput Assist Tomogr; 2010 Jan; 34(1):127-34. PubMed ID: 20118735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-contrast magnetic resonance imaging of hepatocellular carcinoma after transarterial chemoembolization.
    Bolog N; Pfammatter T; Müllhaupt B; Andreisek G; Weishaupt D
    Abdom Imaging; 2008; 33(3):313-23. PubMed ID: 17483983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
    Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
    Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late, and whole triple arterial phase imaging.
    Mori K; Yoshioka H; Takahashi N; Yamaguchi M; Ueno T; Yamaki T; Saida Y
    AJR Am J Roentgenol; 2005 Jan; 184(1):63-9. PubMed ID: 15615952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnetic resonance imaging with gadoxetic acid disodium for the detection of hepatocellular carcinoma: a meta-analysis of 18 studies.
    Chen L; Zhang L; Liang M; Bao J; Zhang J; Xia Y; Huang X; Wang J
    Acad Radiol; 2014 Dec; 21(12):1603-13. PubMed ID: 25262955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detectability of hepatocellular carcinoma on gadoxetic acid-enhanced MRI at 3 T in patients with severe liver dysfunction: clinical impact of dual-source parallel radiofrequency excitation.
    Nishie A; Kakihara D; Asayama Y; Ushijima Y; Takayama Y; Fujita N; Shimamoto D; Shirabe K; Hida T; Honda H
    Clin Radiol; 2015 Mar; 70(3):254-61. PubMed ID: 25522901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma.
    Ooka Y; Kanai F; Okabe S; Ueda T; Shimofusa R; Ogasawara S; Chiba T; Sato Y; Yoshikawa M; Yokosuka O
    Magn Reson Imaging; 2013 Jun; 31(5):748-54. PubMed ID: 23218794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of cirrhotic nodules with gadoxetic acid-enhanced magnetic resonance imaging: the efficacy of hepatocyte-phase imaging.
    Chou CT; Chen YL; Su WW; Wu HK; Chen RC
    J Magn Reson Imaging; 2010 Oct; 32(4):895-902. PubMed ID: 20882620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal scanning protocol of arterial dominant phase for hypervascular hepatocellular carcinoma with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR.
    Kagawa Y; Okada M; Kumano S; Katsube T; Imaoka I; Tanigawa N; Ishii K; Kudo M; Murakami T
    J Magn Reson Imaging; 2011 Apr; 33(4):864-72. PubMed ID: 21448951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data.
    Bonekamp S; Jolepalem P; Lazo M; Gulsun MA; Kiraly AP; Kamel IR
    Radiology; 2011 Sep; 260(3):752-61. PubMed ID: 21771960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging.
    Sano K; Ichikawa T; Motosugi U; Sou H; Muhi AM; Matsuda M; Nakano M; Sakamoto M; Nakazawa T; Asakawa M; Fujii H; Kitamura T; Enomoto N; Araki T
    Radiology; 2011 Dec; 261(3):834-44. PubMed ID: 21998047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatocyte-specific magnetic resonance imaging contrast agents.
    Fidler J; Hough D
    Hepatology; 2011 Feb; 53(2):678-82. PubMed ID: 21274888
    [No Abstract]   [Full Text] [Related]  

  • 33. Can the patient with cirrhosis be imaged for hepatocellular carcinoma without gadolinium?: Comparison of combined T2-weighted, T2*-weighted, and diffusion-weighted MRI with gadolinium-enhanced MRI using liver explantation standard.
    Hardie AD; Kizziah MK; Rissing MS
    J Comput Assist Tomogr; 2011; 35(6):711-5. PubMed ID: 22082541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Education and imaging. Hepatobiliary and Pancreatic: Detection of early hepatocellular carcinoma by enhanced magnetic resonance imaging.
    Eso Y; Marusawa H; Osaki Y
    J Gastroenterol Hepatol; 2012 Feb; 27(2):416. PubMed ID: 22260287
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas.
    Yoon JH; Lee EJ; Cha SS; Han SS; Choi SJ; Juhn JR; Kim MH; Lee YJ; Park SJ
    J Vasc Interv Radiol; 2010 Mar; 21(3):348-56. PubMed ID: 20116285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double-dose gadoxetic Acid-enhanced magnetic resonance imaging in patients with chronic liver disease.
    Motosugi U; Ichikawa T; Sano K; Sou H; Onohara K; Muhi A; Kitamura T; Amemiya F; Enomoto N; Matsuda M; Asakawa M; Fujii H; Araki T
    Invest Radiol; 2011 Feb; 46(2):141-5. PubMed ID: 21139506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study.
    Tsurusaki M; Sofue K; Isoda H; Okada M; Kitajima K; Murakami T
    J Gastroenterol; 2016 Jan; 51(1):71-9. PubMed ID: 26130441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging?
    Kim YK; Kim CS; Han YM; Park G
    Invest Radiol; 2010 Nov; 45(11):740-6. PubMed ID: 20644488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.
    Ahn SS; Kim MJ; Lim JS; Hong HS; Chung YE; Choi JY
    Radiology; 2010 May; 255(2):459-66. PubMed ID: 20413759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proper definitions of MRI contrast enhancement in liver tumors.
    Ni Y; Chen F; Wang H; Feng Y; Li J; Jiang Y
    J Gastroenterol; 2010 Mar; 45(3):349-50; author reply 351-2. PubMed ID: 20012916
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.